{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:49:46Z","timestamp":1776199786813,"version":"3.50.1"},"reference-count":78,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2020,7,17]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel\nclass of non-statin lipid lowering therapy that reduce LDL-cholesterol by 50 - 60%. PCSK9 inhibitors\ndecrease LDL-cholesterol by preventing intracellular degradation of LDL receptors; subsequently, a\ngreater number of LDL-receptors are available on the cell surface to extract circulating LDL.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To describe the origins of PCSK9 inhibitors and their current use in clinical practice.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We performed a narrative review of the PCSK9 inhibitor class of drugs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Current data indicate that PCSK9 inhibitors effectively reduce LDL-cholesterol and are well\ntolerated and safe. PCSK9 inhibitors have also been shown to reduce cardiovascular event rates in\npatients with stable atherosclerotic cardiovascular disease and in patients with a recent (up to one year)\nacute coronary syndrome. Given the costs, chronicity of the treatment and the potential budget impact,\nPCSK9 inhibitors are often limited to patients with the highest absolute risk for major adverse cardiovascular\nevents despite optimal treatment with high-intensity statin and ezetimibe.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>PCSK9 inhibitors have a favorable safety, efficacy and tolerability profile. Postmarketing\nsafety surveillance and real-world studies are needed to further support the long-term safety\nprofile of this class of medicine.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871530320666200213114138","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T16:35:01Z","timestamp":1581611701000},"page":"840-854","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PCSK9 Inhibitors: From Nature\u2019s Lessons to Clinical Utility"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-7938","authenticated-orcid":true,"given":"Frederick J.","family":"Raal","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology and Metabolism, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0195-5063","authenticated-orcid":true,"given":"Robert","family":"Chilton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Division of Cardiology and Interventional Cardiology, University of Texas Health Science Center at San Antonia, Texas, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8299-5176","authenticated-orcid":true,"given":"Naresh","family":"Ranjith","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cardiovascular Research Centre, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-699X","authenticated-orcid":true,"given":"Virendra","family":"Rambiritch","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Health Sciences, Discipline of Pharmaceutical Sciences, University of Kwa-Zulu Natal, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory F.","family":"Leisegang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iftikhar O.","family":"Ebrahim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Netcare Unitas Hospital, Pretoria, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6311-9824","authenticated-orcid":true,"given":"Alet van","family":"Tonder","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Cardiovascular Medicine, Medical Affairs, Sanofi, Midrand, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5258-2132","authenticated-orcid":true,"given":"Nelusha","family":"Shunmoogam","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Cardiovascular Medicine, Medical Affairs, Sanofi, Midrand, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9lia","family":"Bouharati","sequence":"additional","affiliation":[{"name":"Department of Clinical Trials, Clinical Study Unit, Sanofi, Midrand, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6087-5429","authenticated-orcid":true,"given":"Moji G.","family":"Musa","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Cardiovascular Medicine, Medical Affairs, Sanofi, Midrand, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4435-6685","authenticated-orcid":true,"given":"Sumanth","family":"Karamchand","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-1585","authenticated-orcid":true,"given":"Poobalan","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Cardiovascular Medicine, Medical Affairs, Sanofi, Midrand, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-5912","authenticated-orcid":true,"given":"Dirk J.","family":"Blom","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Lipidology and Hatter Institute for Cardiovascular Research in Africa, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","year":"2018","unstructured":"World Health Organization (Accessed on  September 1, 2019).2018"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"Yusuf S.","year":"2004","unstructured":"Yusuf S.; Hawken S.; Ounpuu S.; Dans, T.; Avezum, A.; Lanas, F.; McQueen, M.; Budaj, A.; Pais, P.; Varigos, J.; Lisheng, L. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004,364(9438),937-952","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"Catapano A.L.","year":"2016","unstructured":"Catapano A.L.; Graham I.; De Backer G.; Wiklund O.; Chapman M.J.; Drexel H.; Hoes A.W.; Jennings C.S.; Landmesser U.; Pedersen T.R.; Reiner \u017d.; Riccardi G.; Taskinen M.R.; Tokgozoglu L.; Verschuren W.M.M.; Vlachopoulos C.; Wood D.A.; Zamorano J.L.; Cooney M.T.; ESC scientific document group. 2016 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2016,37(39),2999-3058","journal-title":"Eur Heart J"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/2047487318777079","volume":"25","author":"Danchin N.","year":"2018","unstructured":"Danchin N.; Almahmeed W.; Al-Rasadi K.; Azuri J.; Berrah A.; Cuneo C.A.; Karpov Y.; Kaul U.; Kay\u0131k\u00e7\u0131o\u011flu M.; Mitchenko O.; Ruiz A.J.; Aguilar Salinas C.A.; Santos R.D.; Mercier F.; Blom D.; Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: the international cholesterol management practice study (ICLPS). Eur J Prev Cardiol ICLPS Investigators2018,25(10),1087-1094","journal-title":"Eur J Prev Cardiol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.5551\/jat.31179","volume":"23","author":"Chiang C.E.","year":"2016","unstructured":"Chiang C.E.; Ferri\u00e8res J.; Gotcheva N.N.; Raal F.J.; Shehab A.; Sung J.; Henriksson K.M.; Hermans M.P.; Suboptimal control of lipid levels: Results from 29 countries participating in the centralized pan-regional surveys on the undertreatment of hypercholesterolaemia (CEPHEUS). J Atheroscler Thromb 2016,23(5),567-587","journal-title":"J Atheroscler Thromb"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.09.004","volume":"255","author":"Gitt A.K.","year":"2016","unstructured":"Gitt A.K.; Lautsch D.; Ferrieres J.; Kastelein J.; Drexel H.; Horack M.; Brudi P.; Vanneste B.; Bramlage P.; Chazelle F.; Sazonov V.; Ambegaonkar B.; Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis 2016,255,200-209","journal-title":"Atherosclerosis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/eurheartj\/ehr080","volume":"32","author":"Banegas J.R.","year":"2011","unstructured":"Banegas J.R.; L\u00f3pez-Garc\u00eda E.; Dallongeville J.; Guallar E.; Halcox J.P.; Borghi C.; Mass\u00f3-Gonz\u00e1lez E.L.; Jim\u00e9nez F.J.; Perk J.; Steg P.G.; De Backer G.; Rodr\u00edguez-Artalejo F.; Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011,32(17),2143-2152","journal-title":"Eur Heart J"},{"key":"ref=8","first-page":"1","volume":"16","author":"Blom D.J.","year":"2019","unstructured":"Blom D.J.; Raal F.; Amod A.; Naidoo P.; Lai Y.E.; ICLPS SA study group. Management of low-density lipoprotein cholesterol levels in South Africa: The international cholesterol management practice study (ICLPS). Cardiovasc J Afr 2019,16(30),1-9","journal-title":"Cardiovasc J Afr"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2011.04.018","volume":"216","author":"Cariou B.","year":"2011","unstructured":"Cariou B.; Le May C.; Costet P.; Clinical aspects of PCSK9. Atherosclerosis 2011,216(2),258-265","journal-title":"Atherosclerosis"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","volume":"228","author":"Catapano A.L.","year":"2013","unstructured":"Catapano A.L.; Papadopoulos N.; The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 2013,228(1),18-28","journal-title":"Atherosclerosis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0006-8993(99)01909-5","volume":"848","author":"Seidah N.G.","year":"1999","unstructured":"Seidah N.G.; Chr\u00e9tien M.; Proprotein and prohormone convertases: A family of subtilases generating diverse bioactive polypeptides. Brain Res 1999,848(1-2),45-62","journal-title":"Brain Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"48865","DOI":"10.1074\/jbc.M409699200","volume":"279","author":"Benjannet S.","year":"2004","unstructured":"Benjannet S.; Rhainds D.; Essalmani R.; Mayne J.; Wickham L.; Jin W.; Asselin M.C.; Hamelin J.; Varret M.; Allard D.; Trillard M.; Abifadel M.; Tebon A.; Attie A.D.; Rader D.J.; Boileau C.; Brissette L.; Chr\u00e9tien M.; Prat A.; Seidah N.G.; NARC-1\/PCSK9 and its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004,279(47),48865-48875","journal-title":"J Biol Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"Abifadel M.","year":"2003","unstructured":"Abifadel M.; Varret M.; Rab\u00e8s J.P.; Allard D.; Ouguerram K.; Devillers M.; Cruaud C.; Benjannet S.; Wickham L.; Erlich D.; Derr\u00e9 A.; Vill\u00e9ger L.; Farnier M.; Beucler I.; Bruckert E.; Chambaz J.; Chanu B.; Lecerf J.M.; Luc G.; Moulin P.; Weissenbach J.; Prat A.; Krempf M.; Junien C.; Seidah N.G.; Boileau C.; Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003,34(2),154-156","journal-title":"Nat Genet"},{"key":"ref=14","first-page":"1135","volume":"7","author":"Poirier S.","year":"2013","unstructured":"Poirier S.; Mayer G.; The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther 2013,7,1135-1148","journal-title":"Drug Des Devel Ther"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/CIRCGENETICS.115.001129","volume":"8","author":"Hopkins P.N.","year":"2015","unstructured":"Hopkins P.N.; Defesche J.; Fouchier S.W.; Bruckert E.; Luc G.; Cariou B.; Sjouke B.; Leren T.P.; Harada-Shiba M.; Mabuchi H.; Rab\u00e8s J.P.; Carri\u00e9 A.; van Heyningen C.; Carreau V.; Farnier M.; Teoh Y.P.; Bourbon M.; Kawashiri M.A.; Nohara A.; Soran H.; Marais A.D.; Tada H.; Abifadel M.; Boileau C.; Chanu B.; Katsuda S.; Kishimoto I.; Lambert G.; Makino H.; Miyamoto Y.; Pichelin M.; Yagi K.; Yamagishi M.; Zair Y.; Mellis S.; Yancopoulos G.D.; Stahl N.; Mendoza J.; Du Y.; Hamon S.; Krempf M.; Swergold G.D.; characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody. Circ Cardiovasc Genet 2015,8(6),823-831","journal-title":"Circ Cardiovasc Genet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"Cohen J.C.","year":"2006","unstructured":"Cohen J.C.; Boerwinkle E.; Mosley T.H.; Hobbs H.H.; Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006,354(12),1264-1272","journal-title":"N Engl J Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.tcm.2015.01.009","volume":"25","author":"Desai N.R.","year":"2015","unstructured":"Desai N.R.; Sabatine M.S.; PCSK9 inhibition in patients with hypercholesterolemia. Trends Cardiovasc Med 2015,25(7),567-574","journal-title":"Trends Cardiovasc Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ahj.2016.05.010","volume":"178","author":"Ridker P.M.","year":"2016","unstructured":"Ridker P.M.; Amarenco P.; Brunell R.; Glynn R.J.; Jukema J.W.; Kastelein J.J.; Koenig W.; Nissen S.; Revkin J.; Santos R.D.; Schwartz P.F.; Yunis C.; Tardif J.C.; Studies of PCSK9 inhibition and the reduction of vascular events (SPIRE) investigators. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the studies of PCSK9 inhibition and the reduction of vascular events (SPIRE) lipid lowering and spire cardiovascular outcomes trials. Am Heart J 2016,178,135-144","journal-title":"Am Heart J"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.acvd.2013.10.007","volume":"107","author":"Farnier M.","year":"2014","unstructured":"Farnier M.; PCSK9: From discovery to therapeutic applications. Arch Cardiovasc Dis 2014,107(1),58-66","journal-title":"Arch Cardiovasc Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1161\/CIRCULATIONAHA.116.025233","volume":"135","author":"Toth P.P.","year":"2017","unstructured":"Toth P.P.; Descamps O.; Genest J.; Sattar N.; Preiss D.; Dent R.; Djedjos C.; Wu Y.; Geller M.; Uhart M.; Somaratne R.; Wasserman S.M.; Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies. Circulation PROFICIO Investigators2017,135(19),1819-1831","journal-title":"Circulation"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s40618-019-01019-4","volume":"42","author":"Dicembrini I.","year":"2019","unstructured":"Dicembrini I.; Giannini S.; Ragghianti B.; Mannucci E.; Monami M.; Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Endocrinol Invest 2019,42(9),1029-1039","journal-title":"J Endocrinol Invest"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/fca.14.82","volume":"11","author":"Roth E.M.","year":"2015","unstructured":"Roth E.M.; McKenney J.M.; ODYSSEY MONO: Effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol 2015,11(1),27-37","journal-title":"Future Cardiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"Nissen S.E.","year":"2016","unstructured":"Nissen S.E.; Stroes E.; Dent-Acosta R.E.; Rosenson R.S.; Lehman S.J.; Sattar N.; Preiss D.; Bruckert E.; Ce\u0161ka R.; Lepor N.; Ballantyne C.M.; Gouni-Berthold I.; Elliott M.; Brennan D.M.; Wasserman S.M.; Somaratne R.; Scott R.; Stein E.A.; Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial. JAMA GAUSS-3 Investigators2016,315(15),1580-1590","journal-title":"JAMA"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"Moriarty P.M.","year":"2015","unstructured":"Moriarty P.M.; Thompson P.D.; Cannon C.P.; Guyton J.R.; Bergeron J.; Zieve F.J.; Bruckert E.; Jacobson T.A.; Kopecky S.L.; Baccara-Dinet M.T.; Du Y.; Pordy R.; Gipe D.A.; Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol ODYSSEY ALTERNATIVE Investigators2015,9(6),758-769","journal-title":"J Clin Lipidol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"Schwartz G.G.","year":"2018","unstructured":"Schwartz G.G.; Steg P.G.; Szarek M.; Bhatt D.L.; Bittner V.A.; Diaz R.; Edelberg J.M.; Goodman S.G.; Hanotin C.; Harrington R.A.; Jukema J.W.; Lecorps G.; Mahaffey K.W.; Moryusef A.; Pordy R.; Quintero K.; Roe M.T.; Sasiela W.J.; Tamby J.F.; Tricoci P.; White H.D.; Zeiher A.M.; ODYSSEY OUTCOMES committees and investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018,379(22),2097-2107","journal-title":"N Engl J Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"Sabatine M.S.","year":"2017","unstructured":"Sabatine M.S.; Giugliano R.P.; Keech A.C.; Honarpour N.; Wiviott S.D.; Murphy S.A.; Kuder J.F.; Wang H.; Liu T.; Wasserman S.M.; Sever P.S.; Pedersen T.R.; FOURIER steering committee and investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017,376(18),1713-1722","journal-title":"N Engl J Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1210\/jc.2015-1520","volume":"100","author":"Bays H.","year":"2015","unstructured":"Bays H.; Gaudet D.; Weiss R.; Ruiz J.L.; Watts G.F.; Gouni-Berthold I.; Robinson J.; Zhao J.; Hanotin C.; Donahue S.; Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab 2015,100(8),3140-3148","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","volume":"244","author":"Farnier M.","year":"2016","unstructured":"Farnier M.; Jones P.; Severance R.; Averna M.; Steinhagen-Thiessen E.; Colhoun H.M.; Du Y.; Hanotin C.; Donahue S.; Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis 2016,244,138-146","journal-title":"Atherosclerosis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"895","DOI":"10.5551\/jat.RV17012","volume":"24","author":"Nozue T.","year":"2017","unstructured":"Nozue T.; Lipid lowering therapy and circulating PCSK9 concentration. J Atheroscler Thromb 2017,24(9),895-907","journal-title":"J Atheroscler Thromb"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1093\/eurheartj\/ehv370","volume":"36","author":"Kastelein J.J.","year":"2015","unstructured":"Kastelein J.J.; Ginsberg H.N.; Langslet G.; Hovingh G.K.; Ceska R.; Dufour R.; Blom D.; Civeira F.; Krempf M.; Lorenzato C.; Zhao J.; Pordy R.; Baccara-Dinet M.T.; Gipe D.A.; Geiger M.J.; Farnier M.; ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015,36(43),2996-3003","journal-title":"Eur Heart J"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"Raal F.J.","year":"2015","unstructured":"Raal F.J.; Stein E.A.; Dufour R.; Turner T.; Civeira F.; Burgess L.; Langslet G.; Scott R.; Olsson A.G.; Sullivan D.; Hovingh G.K.; Cariou B.; Gouni-Berthold I.; Somaratne R.; Bridges I.; Scott R.; Wasserman S.M.; Gaudet D.; PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet RUTHERFORD-2 Investigators2015,385(9965),331-340","journal-title":"Lancet"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"Raal F.J.","year":"2015","unstructured":"Raal F.J.; Honarpour N.; Blom D.J.; Hovingh G.K.; Xu F.; Scott R.; Wasserman S.M.; Stein E.A.; Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial. Lancet TESLA Investigators2015,385(9965),341-350","journal-title":"Lancet"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"Robinson J.G.","year":"2015","unstructured":"Robinson J.G.; Farnier M.; Krempf M.; Bergeron J.; Luc G.; Averna M.; Stroes E.S.; Langslet G.; Raal F.J.; El Shahawy M.; Koren M.J.; Lepor N.E.; Lorenzato C.; Pordy R.; Chaudhari U.; Kastelein J.J.; Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med ODYSSEY LONG TERM Investigators2015,372(16),1489-1499","journal-title":"N Engl J Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","volume":"30","author":"Ginsberg H.N.","year":"2016","unstructured":"Ginsberg H.N.; Rader D.J.; Raal F.J.; Guyton J.R.; Baccara-Dinet M.T.; Lorenzato C.; Pordy R.; Stroes E.; Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher. Cardiovasc Drugs Ther 2016,30(5),473-483","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","volume":"169","author":"Kereiakes D.J.","year":"2015","unstructured":"Kereiakes D.J.; Robinson J.G.; Cannon C.P.; Lorenzato C.; Pordy R.; Chaudhari U.; Colhoun H.M.; Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J 2015,169(6),906-915.e13","journal-title":"Am Heart J"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.amjcard.2017.06.023","volume":"120","author":"El Shahawy M.","year":"2017","unstructured":"El Shahawy M.; Cannon C.P.; Blom D.J.; McKenney J.M.; Cariou B.; Lecorps G.; Pordy R.; Chaudhari U.; Colhoun H.M.; Efficacy and safety of alirocumab versus ezetimibe over 2 years (from ODYSSEY COMBO II). Am J Cardiol 2017,120(6),931-939","journal-title":"Am J Cardiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"Koren M.J.","year":"2014","unstructured":"Koren M.J.; Lundqvist P.; Bolognese M.; Neutel J.M.; Monsalvo M.L.; Yang J.; Kim J.B.; Scott R.; Wasserman S.M.; Bays H.; Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol MENDEL-2 Investigators2014,63(23),2531-2540","journal-title":"J Am Coll Cardiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"Robinson J.G.","year":"2014","unstructured":"Robinson J.G.; Nedergaard B.S.; Rogers W.J.; Fialkow J.; Neutel J.M.; Ramstad D.; Somaratne R.; Legg J.C.; Nelson P.; Scott R.; Wasserman S.M.; Weiss R.; Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA LAPLACE-2 Investigators2014,311(18),1870-1882","journal-title":"JAMA"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"Stroes E.","year":"2014","unstructured":"Stroes E.; Colquhoun D.; Sullivan D.; Civeira F.; Rosenson R.S.; Watts G.F.; Bruckert E.; Cho L.; Dent R.; Knusel B.; Xue A.; Scott R.; Wasserman S.M.; Rocco M.; Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol GAUSS-2 Investigators2014,63(23),2541-2548","journal-title":"J Am Coll Cardiol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"Blom D.J.","year":"2014","unstructured":"Blom D.J.; Hala T.; Bolognese M.; Lillestol M.J.; Toth P.D.; Burgess L.; Ceska R.; Roth E.; Koren M.J.; Ballantyne C.M.; Monsalvo M.L.; Tsirtsonis K.; Kim J.B.; Scott R.; Wasserman S.M.; Stein E.A.; A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med DESCARTES Investigators2014,370(19),1809-1819","journal-title":"N Engl J Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","volume":"376","author":"Ridker P.M.","year":"2017","unstructured":"Ridker P.M.; Revkin J.; Amarenco P.; Brunell R.; Curto M.; Civeira F.; Flather M.; Glynn R.J.; Gregoire J.; Jukema J.W.; Karpov Y.; Kastelein J.J.P.; Koenig W.; Lorenzatti A.; Manga P.; Masiukiewicz U.; Miller M.; Mosterd A.; Murin J.; Nicolau J.C.; Nissen S.; Ponikowski P.; Santos R.D.; Schwartz P.F.; Soran H.; White H.; Wright R.S.; Vrablik M.; Yunis C.; Shear C.L.; Tardif J.C.; SPIRE cardiovascular outcome investigators. cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med 2017,376(16),1527-1539","journal-title":"N Engl J Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","volume":"376","author":"Ridker P.M.","year":"2017","unstructured":"Ridker P.M.; Tardif J-C.; Amarenco P.; Duggan W.; Glynn R.J.; Jukema J.W.; Kastelein J.J.P.; Kim A.M.; Koenig W.; Nissen S.; Revkin J.; Rose L.M.; Santos R.D.; Schwartz P.F.; Shear C.L.; Yunis C.; lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med SPIRE investigators2017,376(16),1517-1526","journal-title":"N Engl J Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","volume":"39","author":"Ference B.A.","year":"2018","unstructured":"Ference B.A.; Cannon C.P.; Landmesser U.; L\u00fcscher T.F.; Catapano A.L.; Ray K.K.; Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: An analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J 2018,39(27),2540-2545","journal-title":"Eur Heart J"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rec.2015.08.020","volume":"69","author":"Bueno H.","year":"2016","unstructured":"Bueno H.; Mart\u00edn Asenjo R.; Long-term cardiovascular risk after acute coronary syndrome, an ongoing challenge. Rev Esp Cardiol (Engl Ed) 2016,69(1),1-2","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","volume":"168","author":"Schwartz G.G.","year":"2014","unstructured":"Schwartz G.G.; Bessac L.; Berdan L.G.; Bhatt D.L.; Bittner V.; Diaz R.; Goodman S.G.; Hanotin C.; Harrington R.A.; Jukema J.W.; Mahaffey K.W.; Moryusef A.; Pordy R.; Roe M.T.; Rorick T.; Sasiela W.J.; Shirodaria C.; Szarek M.; Tamby J.F.; Tricoci P.; White H.; Zeiher A.; Steg P.G.; Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY outcomes trial. Am Heart J 2014,168(5),682-689","journal-title":"Am Heart J"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"Silverman M.G.","year":"2016","unstructured":"Silverman M.G.; Ference B.A.; Im, K.; Wiviott, S.D.; Giugliano, R.P.; Grundy, S.M.; Braunwald, E.; Sabatine, M.S. Im, K.; Wiviott, S.D.; Giugliano, R.P.; Grundy, S.M.; Braunwald, E.; Sabatine, M.S.; Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016,316(12),1289-1297","journal-title":"JAMA"},{"key":"ref=47","author":"Jukema J.W.","year":"2019.","unstructured":"Jukema J.W.; Szarek M.; Zijlstra L.E.; de Silva H.A.; Bhatt D.L.; Bittner V.A.; Diaz R.; Edelberg J.M.; Goodman S.G.; Hanotin C.; Harrington R.A.; Karpov Y.; Moryusef A.; Pordy R.; Prieto J.C.; Roe M.T.; White H.D.; Zeiher A.M.; Schwartz G.G.; Steg P.G.; ODYSSEY OUTCOMES committees and investigators Patients with recent acute coronary syndrome and polyvascular disease derive large absolute benefit from alirocumab: ODYSSEY OUTCOMES trial. J Am Coll Cardiol,  S0735-1097(19)33921-X.2019.","journal-title":"J Am Coll Cardiol,"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","volume":"138","author":"Sabatine M.S.","year":"2018","unstructured":"Sabatine M.S.; De Ferrari G.M.; Giugliano R.P.; Huber K.; Lewis B.S.; Ferreira J.; Kuder J.F.; Murphy S.A.; Wiviott S.D.; Kurtz C.E.; Honarpour N.; Keech A.C.; Sever P.S.; Pedersen T.R.; Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease. Circulation 2018,138(8),756-766","journal-title":"Circulation"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"Bonaca M.P.","year":"2018","unstructured":"Bonaca M.P.; Nault P.; Giugliano R.P.; Keech A.C.; Pineda A.L.; Kanevsky E.; Kuder J.; Murphy S.A.; Jukema J.W.; Lewis B.S.; Tokgozoglu L.; Somaratne R.; Sever P.S.; Pedersen T.R.; Sabatine M.S.; Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation 2018,137(4),338-350","journal-title":"Circulation"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"Sabatine M.S.","year":"2017","unstructured":"Sabatine M.S.; Leiter L.A.; Wiviott S.D.; Giugliano R.P.; Deedwania P.; De Ferrari G.M.; Murphy S.A.; Kuder J.F.; Gouni Berthold I.; Lewis B.S.; Handelsman Y.; Pineda A.L.; Honarpour N.; Keech A.C.; Sever P.S.; Pedersen T.R.; Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 2017,5(12),941-950","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1111\/dme.13817","volume":"35","author":"Leiter L.A.","year":"2018","unstructured":"Leiter L.A.; Tinahones F.J.; Karalis D.G.; Bujas-Bobanovic M.; Letierce A.; Mandel J.; Samuel R.; Jones P.H.; Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med 2018,35(12),1742-1751","journal-title":"Diabet Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.amjcard.2016.08.072","volume":"118","author":"Jones P.H.","year":"2016","unstructured":"Jones P.H.; Bays H.E.; Chaudhari U.; Pordy R.; Lorenzato C.; Miller K.; Robinson J.G.; Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. Am J Cardiol 2016,118(12),1805-1811","journal-title":"Am J Cardiol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4172\/2155-9562.1000236","volume":"5","author":"Chen X.","year":"2014","unstructured":"Chen X.; Hui L.; Geiger J.D.; Role of LDL cholesterol and endolysosomes in amyloidogenesis and Alzheimer\u2019s disease. J Neurol Neurophysiol 2014,5(5),236","journal-title":"J Neurol Neurophysiol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"Giugliano R.P.","year":"2017","unstructured":"Giugliano R.P.; Pedersen T.R.; Park J.G.; De Ferrari G.M.; Gaciong Z.A.; Ceska R.; Toth K.; Gouni-Berthold I.; Lopez-Miranda J.; Schiele F.; Mach F.; Ott B.R.; Kanevsky E.; Pineda A.L.; Somaratne R.; Wasserman S.M.; Keech A.C.; Sever P.S.; Sabatine M.S.; Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial. Lancet FOURIER Investigators2017,390(10106),1962-1971","journal-title":"Lancet"},{"key":"ref=55","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.116.003153","volume":"10","author":"Khan A.R.","year":"2017","unstructured":"Khan A.R.; Bavishi C.; Riaz H.; Farid T.A.; Khan S.; Atlas M.; Hirsch G.; Ikram S.; Bolli R.; Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors. Circ Cardiovasc Qual Outcomes 2017,10(1)","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","volume":"37","author":"Lipinski M.J.","year":"2016","unstructured":"Lipinski M.J.; Benedetto U.; Escarcega R.O.; Biondi-Zoccai G.; Lhermusier T.; Baker N.C.; Torguson R.; Brewer H.B.; Waksman R.; The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: A network meta-analysis. Eur Heart J 2016,37(6),536-545","journal-title":"Eur Heart J"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","volume":"129","author":"Koren M.J.","year":"2014","unstructured":"Koren M.J.; Giugliano R.P.; Raal F.J.; Sullivan D.; Bolognese M.; Langslet G.; Civeira F.; Somaratne R.; Nelson P.; Liu T.; Scott R.; Wasserman S.M.; Sabatine M.S.; Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation OSLER Investigators2014,129(2),234-243","journal-title":"Circulation"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"Giugliano R.P.","year":"2017","unstructured":"Giugliano R.P.; Mach F.; Zavitz K.; Kurtz C.; Im, K.; Kanevsky, E.; Schneider, J.; Wang, H.; Keech, A.; Pedersen, T.R.; Sabatine, M.S.; Sever, P.S.; Robinson, J.G.; Honarpour, N.; Wasserman, S.M.; Ott, B.R. EBBINGHAUS Investigators. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med 2017,377(7),633-643","journal-title":"N Engl J Med"},{"key":"ref=59","unstructured":"National Institutes of Health (NIH)). 2020. Available at:(Accessed on September 1, 2019)."},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","volume":"57","author":"Hsia J.","year":"2011","unstructured":"Hsia J.; MacFadyen J.G.; Monyak J.; Ridker P.M.; Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg\/dl with rosuvastatin. The JUPITER trial (justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin). J Am Coll Cardiol 2011,57(16),1666-1675","journal-title":"J Am Coll Cardiol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","volume":"2","author":"Giugliano R.P.","year":"2017","unstructured":"Giugliano R.P.; Wiviott S.D.; Blazing M.A.; De Ferrari G.M.; Park J.G.; Murphy S.A.; White J.A.; Tershakovec A.M.; Cannon C.P.; Braunwald E.; Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: A prespecified analysis of the IMPROVE-IT Trial. JAMA Cardiol 2017,2(5),547-555","journal-title":"JAMA Cardiol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/joim.12614","volume":"281","author":"Olsson A.G.","year":"2017","unstructured":"Olsson A.G.; Angelin B.; Assmann G.; Binder C.J.; Bj\u00f6rkhem I.; Cedazo-Minguez A.; Cohen J.; von Eckardstein A.; Farinaro E.; M\u00fcller-Wieland D.; Parhofer K.G.; Parini P.; Rosenson R.S.; Starup-Linde J.; Tikkanen M.J.; Yvan-Charvet L.; Can LDL cholesterol be too low? Possible risks of extremely low levels. J Intern Med 2017,281(6),534-553","journal-title":"J Intern Med"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","volume":"69","author":"Robinson J.G.","year":"2017","unstructured":"Robinson J.G.; Rosenson R.S.; Farnier M.; Chaudhari U.; Sasiela W.J.; Merlet L.; Miller K.; Kastelein J.J.; Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. J Am Coll Cardiol 2017,69(5),471-482","journal-title":"J Am Coll Cardiol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/CIRCRESAHA.115.307071","volume":"117","author":"Blom D.J.","year":"2015","unstructured":"Blom D.J.; Djedjos C.S.; Monsalvo M.L.; Bridges I.; Wasserman S.M.; Scott R.; Roth E.; Effects of evolocumab on vitamin e and steroid hormone levels: Results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ Res 2015,117(8),731-741","journal-title":"Circ Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1161\/CIRCULATIONAHA.117.028430","volume":"136","author":"Hess G.P.","year":"2017","unstructured":"Hess G.P.; Natarajan P.; Faridi K.F.; Fievitz A.; Valsdottir L.; Yeh R.W.; Proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: Payer approvals and rejections, and patient characteristics for successful prescribing. Circulation 2017,136(23),2210-2219","journal-title":"Circulation"},{"key":"ref=66","author":"Draft Report I.C.E.R.","year":"2017","unstructured":"Draft Report I.C.E.R.;  Available at: 2017","journal-title":"Available at:"},{"key":"ref=67","year":"2017","unstructured":"Institute for Clinical and Economic Review (ICER)2017"},{"key":"ref=68","year":"(Accessed on September 1, 2019).","unstructured":"Alirocumab for treatment of high cholesterol: Effectiveness and valueAvailable at: Institute for Clinical and Economic Review (ICER)(Accessed on September 1, 2019).","journal-title":"Alirocumab for treatment of high cholesterol: Effectiveness and valueAvailable at:"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40273-018-0671-0","volume":"36","author":"Korman M.J.","year":"2018","unstructured":"Korman M.J.; Retterst\u00f8l K.; Kristiansen I.S.; Wisl\u00f8ff T.; Are PCSK9 Inhibitors Cost Effective? Pharmacoeconomics 2018,36(9),1031-1041","journal-title":"Pharmacoeconomics"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","volume":"2","author":"Fonarow G.C.","year":"2017","unstructured":"Fonarow G.C.; Keech A.C.; Pedersen T.R.; Giugliano R.P.; Sever P.S.; Lindgren P.; van Hout B.; Villa G.; Qian Y.; Somaratne R.; Sabatine M.S.; Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2017,2(10),1069-1078","journal-title":"JAMA Cardiol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jama.2017.9924","volume":"318","author":"Kazi D.S.","year":"2017","unstructured":"Kazi D.S.; Penko J.; Coxson P.G.; Moran A.E.; Ollendorf D.A.; Tice J.A.; Bibbins-Domingo K.; Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. JAMA 2017,318(8),748-750","journal-title":"JAMA"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/clc.22924","volume":"41","author":"Baum S.J.","year":"2018","unstructured":"Baum S.J.; Cannon C.P.; PCSK9 inhibitor valuation: A science-based review of the two recent models. Clin Cardiol 2018,41(4),544-550","journal-title":"Clin Cardiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","volume":"39","author":"Landmesser U.","year":"2018","unstructured":"Landmesser U.; Chapman M.J.; Stock J.K.; Amarenco P.; Belch J.J.F.; Bor\u00e9n J.; Farnier M.; Ference B.A.; Gielen S.; Graham I.; Grobbee D.E.; Hovingh G.K.; L\u00fcscher T.F.; Piepoli M.F.; Ray K.K.; Stroes E.S.; Wiklund O.; Windecker S.; Zamorano J.L.; Pinto F.; Tokg\u00f6zoglu L.; Bax J.J.; Catapano A.L.; 2017 Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J 2018,39(14),1131-1143","journal-title":"Eur Heart J"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijcard.2017.10.080","volume":"253","author":"Stam-Slob M.C.","year":"2018","unstructured":"Stam-Slob M.C.; van der Graaf Y.; de Boer A.; Greving J.P.; Visseren F.L.J.; Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. Int J Cardiol 2018,253,148-154","journal-title":"Int J Cardiol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"Nordestgaard B.G.","year":"2013","unstructured":"Nordestgaard B.G.; Chapman M.J.; Humphries S.E.; Ginsberg H.N.; Masana L.; Descamps O.S.; Wiklund O.; Hegele R.A.; Raal F.J.; Defesche J.C.; Wiegman A.; Santos R.D.; Watts G.F.; Parhofer K.G.; Hovingh G.K.; Kovanen P.T.; Boileau C.; Averna M.; Bor\u00e9n J.; Bruckert E.; Catapano A.L.; Kuivenhoven J.A.; Pajukanta P.; Ray K.; Stalenhoef A.F.; Stroes E.; Taskinen M.R.; Tybj\u00e6rg-Hansen A.; European atherosclerosis society consensus panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J 2013,34(45),3478-90a","journal-title":"Eur Heart J"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2017.05.013","volume":"262","author":"Masana L.","year":"2017","unstructured":"Masana L.; Plana N.; P\u00e9rez-Calahorra S.; Ibarretxe D.; Lamiquiz Moneo I.; Pedro-Botet J.; Su\u00e1rez-Tembra M.; Valdivielso P.; Ortega E.; Civeira F.; Dyslipidemia registry of the Spanish arteriosclerosis society. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition? Atherosclerosis 2017,262,107-112","journal-title":"Atherosclerosis"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"Cuchel M.","year":"2014","unstructured":"Cuchel M.; Bruckert E.; Ginsberg H.N.; Raal F.J.; Santos R.D.; Hegele R.A.; Kuivenhoven J.A.; Nordestgaard B.G.; Descamps O.S.; Steinhagen-Thiessen E.; Tybj\u00e6rg-Hansen A.; Watts G.F.; Averna M.; Boileau C.; Bor\u00e9n J.; Catapano A.L.; Defesche J.C.; Hovingh G.K.; Humphries S.E.; Kovanen P.T.; Masana L.; Pajukanta P.; Parhofer K.G.; Ray K.K.; Stalenhoef A.F.; Stroes E.; Taskinen M.R.; Wiegman A.; Wiklund O.; Chapman M.J.; European atherosclerosis society consensus panel on familial hypercholesterolaemia. Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European atherosclerosis society. Eur Heart J 2014,35(32),2146-2157","journal-title":"Eur Heart J"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/MOL.0000000000000488","volume":"29","author":"Smyth N.","year":"2018","unstructured":"Smyth N.; Ramsay M.; Raal F.J.; Population specific genetic heterogeneity of familial hypercholesterolemia in South Africa. Curr Opin Lipidol 2018,29(2),72-79","journal-title":"Curr Opin Lipidol"}],"container-title":["Endocrine, Metabolic &amp; Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/179329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T11:16:08Z","timestamp":1603451768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/179329\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,7,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871530320666200213114138","relation":{},"ISSN":["1871-5303"],"issn-type":[{"value":"1871-5303","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}